Clinical Study of DMT in Healthy Adults

This open-label trial (n=30) seeks to evaluate the acute and subacute effects of inhaled DMT. Participants will be given a low dose (7mg/70kg) and then two hours later a higher dose (49mg/70kg). Participants will not receive psychological support.

Primary outcome measures include the incidence of treatment-emergent adverse events, evaluating clinical and psychiatric acute risks and, physiological measures including heart rate, blood pressure and respiratory rate.

Topic Healthy Subjects
Compound DMT
Country Brazil
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University Federal of Rio Grande do Norte
University Federal of Rio Grande do Norte research with psychedelics has been taking place for the past ten years and more.

Papers

Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial
This open-label, single-ascending, fixed-order dose-response study (n=27) investigates the safety and tolerability of inhaled DMT. The healthy volunteers received varying doses of inhaled DMT (5-60mg). Preliminary findings indicate dose-dependent increases in intensity, valence, and perceptual ratings, with no significant safety concerns, suggesting inhaled DMT as a potentially efficient and safe administration method.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.